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Resumen
A retrospective review of publications about primary vasculitis cases was performed from the Colombian 
medical literature, the clinical and pathological features are described.
The Renal vasculitis occurred in 33.9% of cases of primary vasculitis reviewed and was more frequent in 
women. The main clinical, hematological, immunological variables and nephropathology and immunosu-
ppressive treatments used findings are described.
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Summary
Se realizó una revisión retrospectiva de publicaciones en la literatura médica Colombiana  de los casos con 
Vasculitis Primarias, se describen las características clínicas y patológicas.
La vasculitis Renal se presentó en el 33.9% de los casos de vasculitis primaria revisados y fue más frecuente 
en mujeres. Se describen las principales variables clínicas, hematológicas, inmunológicas  y los hallazgos de 
nefropatología, así como los tratamientos inmunosupresores utilizados.
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Introduction
Primary vasculitides are a heterogeneous group of systemic diseases characterized by inflam-matory cell infiltration in blood vessel walls 
causing destruction and fibrinoid necrosis1. These 
can involve one or more vessels of various calibers, 
hence that the clinical manifestations depend largely 
on which of these arteries are compromised.
According to the etiology, they may be primary, if 
a cause is not identified, or secondary to an infec-
tious process, induced by medication or an autoim-
mune disease2.
With respect to the caliber of the blood vessels, the-
se can be large (aorta and its main branches), me-
dium (smaller vessels that are the main branches of 
the aorta, but still having an intima, elastic lamina, 
tunica media, and adventitia), and small (all those 
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below macroscopic size such as capillaries, post-ca-
pillary venules, venules, andarterioles) in size. 
Among the large vessel vasculitides are Takayasu’s 
arteritis and giant cell arteritis. Those that affect the 
medium caliber include polyarteritis nodosa (PAN), 
Kawasaki disease, and vasculitides of the small ves-
sel or associated with
ANCAs are Wegener's granulomatosis, Churg 
Strauss syndrome, and microscopic polyangiitis 
(MPA). Several attempts to classify the different 
types of systemic vasculitis have been made. The 
first attempt was made by Zeek in 1952 and was ba-
sed according to the size of the blood vessel3. Sub-
sequently, the American College of Rheumatology 
established in
1990 the classification criteria for different forms of 
vasculitis, in an attempt to unify concepts and create 
a uniform scheme to allow inclusion of patients in 
clinical studies4. With the development of knowle-
dge on vasculitis and the association between anti-
neutrophil cytoplasmic antibodies (ANCA) in the 
development of small vessel vasculitis, the Cha-
pel Hill Consensus in 19945 proposed a system of 
nomenclature and definition for the most common 
non-infectious forms of vasculitis. In 2012, this con-
sensus was updated and it was decided to dispense 
with medical eponyms and rename the different vas-
culitis according to their histopathological presenta-
tion, hence Wegener’s granulomatosis was renamed 
granulomatosis with polyangiitis and Churg Strauss 
syndrome was termed eosinophilic granulomatosis 
with polyangiitis6. These classification systems, no-
menclature, and definitions are not diagnostic crite-
ria for the different types of vasculitis, allowing the 
unification of concepts and facilitating the inclusion 
of patients in clinical trials.
The lack of uniformity in concepts, as well as their 
low incidence, has made their study difficult. Howe-
ver it is considered that giant cell arteritis is the most 
common form of systemic vasculitis, being more 
frequent in patients over 50 years of age. Studies 
in populations of Scandinavians and Americans of 
Nordic descent (Olmsted County, Minnesota, USA) 
showed an annual incidence of 15-35/100,000 and 
18.8 / 100,000 in people over 50 years of age7,8. In 
Japan, there was a reported a prevalence of 1.47 / 
100,000 in people over 50 years of age9. Studies su-
ggest that this is predominantly a disease of Cauca-
sians but these studies have been of mainly Scandi-
navian countries and the existence of ethnic studies 
is not known.
Kawasaki disease has been best studied in Ja-
pan, where they have documented an incidence of 
100/100,000 of children younger than 5 years old10, 
and in another Asian country like China, there have 
been incidences as high as 18-27.8 / 100,000 in Bei-
jing and as low as 2.4 / 100,000 in Shanxi in children 
younger than 5 years old11,12. Studies in the United 
States and in England have found annual incidences 
of 8-18/100.000 and 4-8/100.000 respectively. Esti-
mates have been made to determine the prevalence of 
PAN. In France, it is considered to be 30/1,000,000 
and in Sweden 1.6/1,000,00013, while the incidence 
in Australia is 1.1 / 1,000,000 per year14.
Epidemiological studies of this entity have been di-
fficult given the changes in the definition of patho-
logy. Additionally it has been observed that a large 
number of these cases have been associated with the 
presence of HBV infection, especially in Asia.
As for small vessel vasculitis, granulomatosis with 
polyangiitis has an annual incidence that varies by re-
gion from 0.5-8 cases/1,000,000, being higher in some 
European countries such as Sweden and Finland15,16. 
In Latin America, particularly in Peru, there is a repor-
ted incidence of 0.5 cases per million17.
The microscopic polangiitis is an entity that is ge-
nerally lower in frequency than granulomatosis with 
polyangiitis. In the UK, the incidences reported vary 
from 3.3-8.9/1,000,00018,19, which when compared 
with the data in other countries shows a higher pre-
valence and incidence in these populations.
Eosinophilic granulomatosis with polyangiitis has 
an overall incidence of 1-3 cases / million. It is the 
least common of the ANCA-associated vasculitis, is 
more common in women, with a peak onset of 65-
75 years of age. With the exception of a report by 
Sanchez et al in Peru, the epidemiology of primary 
vasculitis in Latin America is scarce.
In Bogota, Colombia there was the opportunity to re-
cover a historical cohort of San Juan de Dios Hospi-
tal of 165.556 biopsies, of which 104 corresponded 
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to primary vasculitis and of these 79 corresponded 
to small vessel vasculitis with a frequency of 47.2 / 
100,000 biopsies20. This demonstrates the need for 
population studies to identify the frequency of vas-
culitis in the Colombian population.
Epidemiologic studies of impaired renal function 
in AAV are scare and reports come from Norwich 
(England), Lugo (Spain), Sweden, and Miyazaki 
prefecture in Japan.
The aim of the present study was to retrospectively 
analyze all the renal vasculitis cases collected by our 
group, in order to identify the most important featu-
res of this entity in Colombia.
Methods
This is a descriptive and retrospective study. The aim 
of the study was to identify all the patients attending 
the Rheumatology Department of the Universidad 
Nacional de Colombia (Bogotá, Colombia) as out-
patients or hospitalized with a diagnosis of primary
systemic vasculitis from 2000 until 2010. Also, we 
invited other Rheumatology units in Colombia to 
send us new cases of vasculitis that they have iden-
tified. The medical records from every case recog-
nized were reviewed retrospectively to confirm the 
vasculitis classification using the Chapel Hill Con-
sensus Conference definitions.
Inclusion criteria for the present study were: 1) Pa-
tients with a diagnosis of primary systemic vasculitis 
with or without histological confirmation; 2) Renal 
involvement suspected by hematuria, proteinuria, 
or both with or without renal insufficiency, and/or 
pathological changes in renal biopsies supporting 
renal vasculitis. From every case of renal vasculitis 
the gender, age, type of vasculitis, laboratory fin-
dings (including ANCAs), treatment, features from 
renal biopsies, and outcomes were recorded. Theda-
ta from the study were presented as mean, frequen-
cies, and percentages. This study was approved by 
the Research Ethics Committee at the Universidad 
Nacional de Colombia.
Results
We identified and collected 175 patients with primary 
vasculitis. Most of patients were women (63.7%). 
The most frequent vasculitides were TA (21.8%), 
PAN (18.9%), WG (14.9%) and MPA (14.9%), with 
overall average ages of 28.3 (+14.6), 48.2 (+20.5), 
45 (+10.9) and 42.9 (+14.4) respectively (Table 1). 
Those patients with vasculitis associated to ANCAs 
(AAV) such as MPA and WG had positive p-ANCA 
(73.9%) andpositive c-ANCA (84.9%) respectively.
There were 59 cases with renal involvement (33.9%), 
mainly MPA (38.9%) and GW (32%), and to a lesser 
extent PAN (11.8%) and HSP (10%). Of the vascu-
litides associated to ANCAs (AAV), 69.5% of MPA 
with renal impairment were p-ANCA positive and 
68.4% of GW were c-ANCA positive. To note, 10 
cases from PAN were p- ANCA positive but only 6 
had renal involvement. Also, 7 patients with Henoch 
Schölein Purpura had renal involvement but none 
were ANCA positive (Table 2).
Primary vasculitis with renal involvement was found 
mainly in women (59% vs 41%), however, the WG 
cases occurred mostly in men (68% vs 32%) (Table 
2). The age of diagnosis, as expected, was over 40 
years old, with an exception of patients with HSP, 
which is a disease of younger people.
Laboratory findings from these patients show a ten-
dency to have low levels of hemoglobin and high 
levels of leucocytes, platelets, and globular sediment 
rate as well. In MPA, low renal function was very 
important (Table 3). 
Renal involvement of vasculitis was treated with glu-
cocorticoids in 100 % of cases, and often required 
cyclophosphamide (>80%). Renal biopsies were ob-
tained from 37 patients (62%) with vasculitis and re-
nal involvement, mostly from MPA (54%) (Table 3).
Discussion
Primary vasculitis is a group of disorders characteri-
zed by destructive wall vessel inflammation. Many 
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Table 1
Frequency of primary vasculitis in Colombia, serologic features and renal involvement.
Primary vasculitis N Gender M/F Age  P ANCA +  C ANCA + Renal involvement
Large vessel
Takayasu’s arteritis  38  2/24  28.30 (+14.6)  1  0  2
Giant cell arteritis  6  2/4  64.6 (+11.63)  0  1  0
Medium vessel
Kawasaki arteritis  5  2/3  2.76 (+2.52)  0  0  1
Panarteritis nodosa  33  11/22  48.27 (+20.51)  10  1  6
Small vessel
Wegener’s granulomatosis  26  15/11  45 (+10.9)  2  17  19
Microscopic polyangiitis  26  10/16  42.95 (+14.4)  17  7  23
Churg-Strauss syndrome  7  3/2*  43.16 (+13.28)  1  0  0
Henoch-Schonlein purpura  12  2/10  17.45 (+ 6.69)  0  0  7
Cryoglobulinemia  1  0/1  N/A  0  0  1
Urticarial vasculitis  4  1/3  36.5 (+20.14)  0  0  0
Nervous system vasculitis  7  5/2  27 (+ 8.51)  0  0  0
Nodular vasculitis  3  1/2  27 (+ 9.29)  0  0  0
Buerger’s  2  1/1  19 (+1.41)  0  0  0
Leukocytoclastic vasculitis  4  2/2  29  0  0  0
Total  174    31  26  59
*: Missing data
Table 2
Serologic features of Colombian patients with primary vasculitis and renal involvement.
Primary vasculitis Renal  C ANCA + P ANCA + 
 involvement  Age and Renal and Renal Renal 
 Male    Female   involvement involvement biopsy
Wegener’s granulomatosis  13  6  41.16 (+ 10.46)  13  1  7
Microscopic polyangiitis  9  14  42.13 (+ 15.66)  6  16  20
Henoch-Scholein purpura  0  7  21 (+ 5.19)  0  0  7
Cryoglobulinemia  0  1  N/A  0  0  1
Takayasu’s arteritis  0  2  38 (+ 21.12)  0  0  0
Panarteritis nodosa  1  5  57 (+ 11.14)  1  2  2
Kawasaki disease  0  1  2  0  0  0
Total  23  36   20  19  37
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attempts have been made in order to define and clas-
sify those pathologies, such as the ACR proposal 
(1990) and Chapel Hill Concensus (1994), primarily 
by the size of vessel affected in each entity. There 
is very little informationabout the epidemiology of 
primary vasculitis because of its low prevalence 
worldwide.
Primary vasculitis can affect the kidney with diffe-
rent degrees of severity, whether bycompromising 
the renal arteries (vasculitis of large and medium 
vessels) or at thevcapillary level renal glomerulus 
as in small vessel vasculitis associated with AN-
CAvneutrophil antibodies. The latter will predomi-
nantly present renal involvement withv varying de-
grees of severity and frequency.
ANCA-associated vasculitides (AAV) are multisys-
tem diseases, which affect small and medium sized 
vessels and are characterized by the presence of an-
ti-neutrophil cytoplasmic antibodies (ANCAs). The-
se antibodies are directed against neutrophil granule 
proteins and macrophage proteins. According to the 
pattern of staining in indirect immunofluorescence, 
there are cytoplasmic or c-ANCA (mainly direc-
ted against proteinase-3, PR3) and perinuclear or 
p-ANCA (mainly directed againstmyeloperoxidase, 
MPO). These antibodies are associated with the de-
velopment of renal involvement and are factors of 
the aggressiveness and, likewise, the prognosis in 
the course of the disease. Although both patterns are 
found in AAV, the c-ANCA pattern is more common 
in granulomatosis with poliangiits in about 70-80% 
of patients, the p-ANCA in PAM in 60% of patients, 
and eosinophilic granulomatosis with polyangiitis in 
about 40% of patients21.
The typical presentation of AAV is a rapidly progres-
sive glomerulonephritis with renal function loss of 
over 50% in a few days or weeks, acute renal failure, 
hematuria, red cell casts, and non-nephrotic range 
proteinuria, with slight changes in blood pressure22.
The importance lies in that about 60% of patients 
who at diagnosis may require renalreplacement the-
rapy23 and the presence of RPGN is associated with 
a poor shorttermfunctional prognosis, chronic renal 
disease, requirement for renal replacement therapy, 
Table 3
Laboratory features and treatment of Colombian patients with primary vasculitis and renal involvement.
Primary 
vasculitis  Laboratories     Treatment
 Hemoglobin Leukocytes x Platelets x ESR mm/hr Creatinine Steroids  AZA  CyC  Dialysis 
 gr/dl 103 x mm3 mm3   mg/dl
Wegener’s 10.5 (+2.2)  9747 (+3681) 410533 59.7 (+23.3) 1.52 19  7  17  2 
granulomatosis   (+170737)  (+0.16)
Microscopic  13570 310578 33.64 (+22.7)  8.95 (+5.5)  23  13  20  1 
poliangiitis 10.9 (+2.7) (+10269) (+167449)
Henoch-Scholein  10728 301000 25 (+7.5)  N/A  5  1  3  0 
purpura 13 (+3.56) (+4704) (+58024)
Cryoglobulinemia  12,1  3700  165000  13  N/A  1  0  1  0
Takayasu’s 
arteritis 11.5 (+1.13)  8600 (+4666)  307000  49.5(+13.43)  N/A  2  1  0  0
Panarteritis  16360 527600 
nodosa 10.9 (+1.5) (+5210) (+299367) 53.66(+34.11)  N/A  6  5  4  0
Kawasaki disease
N/A 8900 309000 43 N/A 1 0 0 0
N/A: Not available, ESR: Erythrocyte sedimentation rate, AZA: azathioprine, CyC: cyclophosphamide
Rev. Colomb. Nefrol. 2015; 2(1): 3 - 11
Renal vasculitis in Colombia8
and death if not treated early with immunosuppres-
sive therapy24.
The polyangiitis with granulomatosis and micros-
copic polyangiitis are the AAV which most often 
affect the kidney. There are different reports which 
document up to 70% of renal involvement in gra-
nulomatosis with polyangiitis, while in microscopic 
polyangiitis nearly 100% of patients develop renal 
involvement. This is not a very common finding in 
eosinophilic granulomatous polyangiitis where kid-
ney involvement can be seen in up to 25%. Histo-
logically this renal involvement is characterized by 
necrosis of capillary loops, crescent-shaped extraca-
pillary proliferation, periglomerular and interstitial 
infiltration, necrotizing arteritis with the absence of 
autoimmune deposits25 with immunofluorescence. 
However electron microscopy has shown an increa-
se in thefrequency of immunoglobulin deposits, a 
finding that is related to the extent of proteinuria26.
Although these histopathologic findings have been 
well characterized, the etiology of ANCA associated 
vasculitis has not yet been fully determined. Several 
environmental factors have been associated with the 
development of ANCAs. Silica exposure has been 
demonstrated in animal models to induce and increa-
se the speed of apoptosis of neutrophils and mono-
cytes, and this increased apoptosis has been linked 
to the production of ANCAs27. Bacterial infections, 
mainly by S. aureus, can induce AAV.
Several mechanisms have been proposed including 
induction of production of antiproteinase 3, throu-
gh molecular mimicry mechanisms28. Additionally, 
certain medications such as antithyroid agents, car-
bimazole, methimazole and propylthiouracil,have 
been associated with AAV. The latter is related to the 
development of MPOANCA, with reported inciden-
ces ranging from 0.53 to 0.79 per 100,000 patients 
with severe disease29. However, such ANCAs have 
lower pathogenicity and clinicalmanifestations are 
less severe and tend to disappear when the drug is 
stopped30.
The main goal of the Rheumatology Department of 
the Universidad Nacional de Colombia was to reco-
ver every case of primary vasculitis published in me-
dical literature and record each case identified by our 
group and by external Rheumatology groups in Co-
lombia, attending outpatients or hospitalized cases. 
A previous study published by our group reviewed 
all the biopsies from the Pathology Department da-
tabase of the San Juan de Dios Hospital (Bogotá, 
Colombia). A total of 857 cases of primary vascu-
litis were identified, mostly TA (13.3%), Buerger’s 
(11.2%) and cutaneous vasculitis and PAN (10% 
both). Another study published by our group sear-
ched Latin American literature from Pubmed, BIRE-
ME, LILACS, and other databases, and found 1605 
cases of vasculitis. We showed that Mexico and Bra-
zil had mainly Takayasu’s arteritis, and Chile and 
Peru had MPA. The article also mentions how se-
veral diagnoses, such as MPA, have been increasing 
in the last decades. It may be because the vasculitis 
classification criteria and definitions have evolved 
over time as knowledge increases.
There is also scarce information about renal invol-
vement secondary to primary vasculitis. There are a 
few studies from Norwich (England), Lugo (Spain), 
Sweden, and Mizayaki (Japan). The majority of pa-
tients with renal vasculitis are classified as MPA in 
the Mizayaki prefecture, where they had a renal vas-
culitis incidence of 14.8/million. Norwich’s study 
reported an incidence of 5/million, 5.8/million and 
1.4/million of MPA, WG and CSS vasculitis respec-
tively. In Sweden, the incidence of WG was 9.8/mi-
llion and MPA 10.1/million, with renal involvement 
in 48% and 98% of cases respectively. Similarly, our 
study now confirms that small vessel vasculitis is the 
most important cause of renal vasculitis. Of all the 
patients collected with vasculitis and renal involve-
ment (59/174), 38.9% and 32% of patients had MPA 
and WG, respectively. This result was predictable, 
because the kidney is made by small vessels.
The average peak age at presentation for AAV is be-
tween 65 to 74 years old in the European and Ja-
panese cohorts. However our study revealed a peak 
incidence in the fourth decade of life for Colombian 
patients. World literature has not found any differen-
ces among gender and AAV, but interestingly, this 
study suggests that Colombian males are prone to 
develop MPA with renal involvement.
Results from ANCA analysis showed 65.3% (17/26) 
of patients with WG were positive for c-ANCA and 
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65.3% (17/26) of patients with MPA were positive for 
p-ANCA, which is close to international standards. 
Renal involvement was seen in 73% (19/26) of pa-
tients with WG and 88.4% (23/26) of patients with 
MPA, respectively. Also 68.4% (13/19) of patients 
with WG positive for c-ANCA had renal involve-
ment, and 69.5% (16/23) were positive of p-ANCA. 
Renal function was impaired in both entities, espe-
cially MPA, but only 3.3% required dialysis. Addi-
tionally, 10 patients (16.9%) had diagnosis of PAN 
and were positive for p-ANCA, and two of them had 
renal involvement. Our group believes that those pa-
tients may actually have had MPA but during 1990s 
the definitions of both pathologies were not clear 
and they could be misclassified. In fact, fewer cases 
of PAN and more of MAP diagnosis have been made 
last years in Colombia.
Other laboratory findings in patients with primary 
vasculitis and renal involvement showed anemia, 
leukocytosis, thrombocytosis and an elevated ESR, 
all of which characterize an inflammatory state.
Due to the lack of epidemiologic information about 
renal vasculitis, especially in Latinoamerican coun-
tries, our group considers that it is very important 
to identify new cases and collect information from 
patients as much as it is possible, in order to gain 
more knowledge about these entities. The present 
study is the first data (with demographic and sero-
logic features) collected from Colombian patients 
with renal
vasculitis. However, the number of cases collected 
and the retrospective nature of this study reduces the 
power of the results. Also, many cases came from 
other Rheumatology units and it was difficult to ex-
tract this information. On the other hand, renal vas-
culitis is a rare condition and has a heterogeneous 
epidemiology (with prevalences and incidences var-
ying among countries, ethnic disparities, etc) which 
makes this study very important.
These data need to be confirmed in prospective ra-
ther than retrospective studies, collecting cases not 
only from the Rheumatology Department of the 
Universidad Nacional de Colombia, but also from 
other units of Rheumatology and Nephrology in Co-
lombia.
Conclusion
This is the first epidemiologic study to evaluate renal 
vasculitis in Colombia. The most common causes of 
renal vasculitis are WG and MPA. The presence of 
c-ANCA and p-ANCA are associated to both disea-
ses respectively, as international literature describes. 
Prospective studies are required to confirm data.
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